Tag Archives: CACC

Top 10 Heal Care Stocks To Invest In 2023

By Kosaku Narioka

Recruit Holdings Co. shares rose sharply Tuesday morning after the owner of Indeed and Glassdoor job sites said it would buy back up to 150.0 billion yen ($1.01 billion) of its own shares to boost shareholder returns.

The shares were recently 4.2% higher at Y4,436 after rising as much as 5.8% earlier.

Recruit said Monday after market close that it would repurchase up to 2.5% of its outstanding shares from Oct. 18, 2022 to March 14, 2023 and that it aimed to improve capital efficiency and shareholder returns at a time when concerns have grown about the....More>>>

Hot Clean Energy Stocks To Buy For 2021

Equities research analysts expect W. R. Berkley Corp (NYSE:WRB) to post earnings of $0.85 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for W. R. Berkley’s earnings, with the highest EPS estimate coming in at $0.91 and the lowest estimate coming in at $0.75. W. R. Berkley reported earnings of $0.36 per share in the same quarter last year, which indicates a positive year over year growth rate of 136.1%. The firm is expected to announce its next earnings report on Tuesday, October 23rd.

On average, analysts expect that W. R. Berkley....More>>>

Top Safest Stocks To Own For 2019

Whenever the stock market marches higher, it pushes the prices of many companies higher along with it. But as investors bid up good and bad businesses alike, that can make it hard to discern which companies are the best dividend stocks for long-term investors.

That’s especially true in the world of dividend stocks, where income-starved investors face great temptation to reach for high-dividend stocks that offer juicy yields.

Fortunately, Simply Safe Dividends identified the 10 best dividend growth stocks that investors can rely on for secure, fast-growing income.

These....More>>>

Top 10 Medical Stocks For 2019

Small cap regenerative medicine stock RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) has just reported compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use ofthe Companys type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. The clinical trial met its goal of establishing a complete safety profile at 6 months. More importantly, there wereno serious adverse events related to the study treatment or injection procedure.

Tendinosis, sometimes called chronic tendinitis, chronic tendinopathy....More>>>

Hot Undervalued Stocks To Own For 2018

Description of the opportunity and investment thesis

CRHM represents a compelling risk/reward opportunity in the form of a rapidly growing leader in anesthesiology services for GIs in the US and Canada. We believe the company is undervalued on an absolute and relative basis, currently trading at a dramatically low multiple of current and future estimated free cash flow. Given the companys niche position in their market, stable business model, long runway for growth, and fears surrounding short-term operational results, we feel weve been provided with a solid margin of safety at....More>>>